Flooded by the torrent: the COVID-19 drug pipeline

In the months since COVID-19 has spread, researchers have launched more than 180 clinical trials of everything from repurposed antivirals and immunomodulators to unproven cell therapies and vitamin C. A further 150 trials are preparing to recruit patients. Is that a good use of resources?” asks Dani...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet 2020-04, Vol.395 (10232), p.1245-1246
Main Author:	Mullard, Asher
Format:	Article
Language:	eng
Subjects:	Adult Antiretroviral drugs Antiviral agents Antiviral Agents - therapeutic use Antiviral drugs Ascorbic acid Betacoronavirus Clinical trials Collaboration Coronavirus Infections - drug therapy Coronaviruses COVID-19 Drugs Humans Hygiene Immunomodulation Immunomodulators Infectious diseases Lopinavir Medical research Medicine Pandemics Patients Pneumonia, Viral Public health R&D Regulatory approval Research & development Ritonavir RNA polymerase SARS-CoV-2 Subgroups World Report
Online Access:	Request full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In the months since COVID-19 has spread, researchers have launched more than 180 clinical trials of everything from repurposed antivirals and immunomodulators to unproven cell therapies and vitamin C. A further 150 trials are preparing to recruit patients. Is that a good use of resources?” asks Daniel Bausch, director of the UK Public Health Rapid Support Team and infectious disease expert at the London School of Hygiene & Tropical Medicine. First results could be available within 12–16 weeks, insiders say. A 200-patient trial of the lopinavir plus ritonavir combination has already failed, Cao and colleagues reported in the New England Journal of Medicine in March, although subgroup analyses of the data suggest the drugs might still have efficacy.
ISSN:	0140-6736 1474-547X